newsfilter
← Latest News
GlobeNewswire·

Viela Bio Announces Final Results from Phase 1b Trial of VIB7734 in Patients with Cutaneous Lupus Erythematosus

-- VIB7734 potently depleted blood and tissue resident plasmacytoid dendritic cells, an important source of inflammatory mediators in autoimmune diseases -- -- Treatment with VIB7734 resulted in...